Immuneering (IMRX) Chief Accounting Officer Reports 300-Share Purchase

Rhea-AI Filing Summary

Insider purchase reported: Immuneering Corp (IMRX) Chief Accounting Officer Mallory Morales reported acquiring 300 shares of Class A common stock on 10/01/2025 at a price of $6.39 per share. After the transaction, Morales beneficially owns 27,533 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025. No derivative transactions or additional remarks were reported in the filing.

Positive

• Insider purchase reported: Chief Accounting Officer acquired 300 shares, which can be interpreted as a signal of some insider confidence
• Timely disclosure: Form 4 filed and signed, meeting reporting requirements

Negative

• None.

Insights

Financial Analyst

TL;DR Insider purchased a small number of shares; transaction size is immaterial to company valuation.

The filing shows a direct purchase of 300 shares at $6.39, bringing total beneficial ownership to 27,533 shares. For a public company, this size of acquisition by a senior officer is modest and unlikely to change investor perception or financial forecasts. There are no derivative transactions or dispositions reported, and no additional context about financing or planned future purchases.

Corporate Governance Expert

TL;DR Routine Section 16 disclosure; timely filing and signature by attorney-in-fact observed.

The Form 4 appears properly completed for a single non-derivative purchase and was signed on 10/02/2025. The report indicates the reporting person is an officer (Chief Accounting Officer). There are no red flags such as late reporting noted within the document itself, nor any complex ownership structures or indirect holdings disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Morales Mallory

(Last) (First) (Middle)

C/O IMMUNEERING CORPORATION

245 MAIN STREET, SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/01/2025		P		300	A	$6.39	27,533	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Mallory Morales	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IMRX insider Mallory Morales report on Form 4?

Mallory Morales reported purchasing 300 shares of Class A common stock on 10/01/2025 at $6.39 per share, increasing beneficial ownership to 27,533 shares.

How many shares does Mallory Morales own after the transaction?

27,533 shares of Class A common stock following the reported purchase.

Was the Form 4 for IMRX timely signed and filed?

The form was signed by an attorney-in-fact on 10/02/2025; the filing shows the required signature and date.

Were any derivative securities reported by the IMRX insider?

No derivative transactions were reported in Table II of the Form 4.

What price did the IMRX insider pay per share?

$6.39 per share for the 300 shares acquired on 10/01/2025.